Skip to main content

liraglutide

Generic: LIRAGLUTIDE·Brand: LIRAGLUTIDE, SAXENDA, Saxenda, VICTOZA

liraglutide: 6 clinical trials tracked.

liraglutide evidence translation

What we can confirm

6 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about liraglutide, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 1 study sponsors
Clinical Trial Registry Records (6)

Investigation of the Effect of Fasting Duration and Temporary Withholding of GLP-1 RAs on Retained Gastric Contents in Participants Treated With s.c. Liraglutide, Oral Semaglutide or s.c. Semaglutide

NCT07225816Registry updated 2026-07-21·Phase 1·NVO
Recruiting

Primary endpoint: Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal after dosing of subcutaneous (s.c.) liraglutide once daily (Yes/No)

Interventionalopen71 targetStarted 2025-11Completion 2027-011 site · United StatesNovo Nordisk A/S

Multicentre, Single-arm, Non-interventional Regulatory Post- Marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.

NCT06283641Registry updated 2026-01-09·NVO
Completed

Primary endpoint: Incidence of adverse events (AEs) by preferred term (PT)

Observational300 enrolledStarted 2024-04Completion 2025-0115 sites · TaiwanNovo Nordisk A/S

Effectiveness of Semaglutide 2.4 mg vs. Commercially Available Medications for Chronic Weight Management in Participants With Obesity in a Multi-employer Setting in The US - a Pragmatic Clinical Study

NCT05579249Registry updated 2026-01-14·Phase 4·NVO
Completed

Primary endpoint: Number of Participants Who Achieved Greater Than or Equal to (≥) 10.0 Percent (%) Body Weight Reduction (Yes/no)

InterventionalRandomizedopen500 enrolledStarted 2023-01Completion 2024-111 site · United StatesNovo Nordisk A/S

Effects of Liraglutide, Empagliflozin and Linagliptin on Mild Cognitive Impairment Remission in Type 2 Diabetes (LIGHT-MCI): A Multicentre, Randomised Controlled Trial With An Extension Phase

NCT05313529Registry updated 2026-01-06·N/A
Active, not recruiting

Primary endpoint: Mild cognitive impairment (MCI) remission rate

InterventionalRandomizedopen396 targetStarted 2022-10Completion 2026-075 sites · ChinaThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Effect and Safety of Liraglutide 3.0 mg on Weight Management in Children With Obesity Aged 6 to Below 12 Years: 56-week, Double-blind, Randomised, Placebo-controlled Trial

NCT04775082Registry updated 2026-07-09·Phase 3·NVO
Active, not recruiting

Primary endpoint: Relative change in BMI (Body mass index)

InterventionalRandomizedquadruple78 targetStarted 2021-03Completion 2027-0232 sites · Belgium, India, Israel, Malaysia…Novo Nordisk A/S

Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients

NCT02773355Registry updated 2026-04-13·NVO
Completed

Primary endpoint: Frequency of pancreatitis

Observational27 enrolledStarted 2016-05Completion 2022-0214 sites · MexicoNovo Nordisk A/S